Research
Browse or search our latest peer-reviewed research publications.
Identification of Cost-Effectiveness Evidence in UK NICE Single Technology Assessment Company Submissions: Databases, Sources and Currency of Searching
ISPOR US 2024: Poster Session: 1. May 6th 2024. Poster Session Time: 10:30-13:30. Discussion Period: 12:30-13:30.
European Health Technology Assessment: Historical Success of European Joint Assessments
ISPOR US 2024: Poster Session: 1. May 6th 2024. Poster Session Time: 10:30-13:30. Discussion Period: 12:30-13:30.
Systematic Literature Review Requirements for Health Technology Assessment in European Markets
ISPOR US 2024: Poster Session: 3. May 7th 2024. Poster Session Time: 10:30-13:30. Discussion Period: 12:30-13:30.
Comparison of the Use of Real-World Evidence for Clinical Effectiveness in HTA Pre- and Post- Introduction of the NICE Framework – an Update
ISPOR US 2024: Poster Session: 3. May 7th 2024. Poster Session Time: 10:30-13:30. Discussion Period: 12:30-13:30.
A Comparative Assessment of Systematic Literature Review Requirements for Health Technology Assessment, Globally
ISPOR Europe 2023: Poster Session: 5. 15 November 2023. Poster Session Time: 9:00 - 11:30. Discussion Period: 9:00 - 10:00.
Surrogate Endpoints Used in NICE Technology Appraisals for Oncology and Non-Oncology Indications, 2022–23
ISPOR Europe 2023: Poster Session: 1. 13 November 2023. Poster Session Time: 10:30-13:30. Discussion Period: 12:30-13:30.
Comparison of the Use of Real-World Evidence for Clinical Effectiveness in HTA Pre- and Post- Introduction of the NICE Framework
ISPOR Europe 2023: Poster Session: 5. 15 November 2023. Poster Session Time: 9:00-11:30. Discussion Period: 9:00-10:00
Challenges and Solutions to Estimating Environmental Impact in Health Technology Assessment
ISPOR Europe 2023: Poster Session: 4. 14 November 2023. Poster Session Time: 15:30-18:30. Discussion Period: 16:00-17:00
Trends in clinical evidence for digital health applications (DiGa) reimbursed in the German DiGa directory
Skeldon G, Dobson J, Adkins E. Trends in clinical evidence for digital health applications (DiGa) reimbursed in the German DiGa directory. Poster presented at ISPOR Europe; 6-9th November 2022; Vienna: Austria, 2022
The increasing use of population-adjusted indirect comparisons in the NICE Health Technology Assessment (HTA) submission process and the response to these methods
Pooley N, Kisomi M, Embleton N, Langham S. The increasing use of population-adjusted indirect comparisons in the NICE Health Technology Assessment (HTA) submission process and the response to these methods (CO163). Poster presented at ISPOR Europe; 6-9th November 2022; Vienna: Austria, 2022
Is evidence on environmental impact included in health technology assessment and does it influence decision-making?
Hubbert L, Embleton N, Wright A, Nicholson L. Is evidence on environmental impact included in health technology assessment and does it influence decision-making? (HTA56). Poster presented at ISPOR Europe; 6-9th November 2022; Vienna: Austria, 2022
Health technology assessment and reimbursement of medical devices in England, France, and Germany
Heptinstall A, Teague R. Health technology assessment and reimbursement of medical devices in England, France, and Germany (HTA243). Poster presented at ISPOR Europe; 6-9th November 2022; Vienna: Austria, 2022
A review of NICE Medtech Innovation Briefings (MIBS) of digital health technologies
Skeldon G, Adkins E, Teague R. POSB291 A review of NICE Medtech Innovation Briefings (MIBS) of digital health technologies. Value Health 2021;24(S2).
Impact of health technology assessment on prescribing patterns of inhaled fixed-dose combination triple therapy in chronic obstructive pulmonary disease
Cook J, Bloom C, Lewis J, Marjenberg Z, Hernando Platz J, Langham S. Impact of health technology assessment on prescribing patterns of inhaled fixed-dose combination triple therapy in chronic obstructive pulmonary disease. J Mark Access Health Policy 2021;9(1):1929757
Patient engagement process in rare disease: how does it differ between countries?
Skeldon G, Adkins E, Ayre S, Langham S, Nicholson L. PRO95 Patient engagement process in rare disease: how does it differ between countries? Value Health 2020;23(Suppl 2):S706
The increasing use and acceptance of alternative statistical approaches to indirect comparison in the NICE HTA submission process
Pooley N, Marjenberg Z, Embleton N, Langham S. The increasing use and acceptance of alternative statistical approaches to indirect comparison in the National Institute of Health and Care Excellence (NICE) health technology assessment (HTA) submission process. Value Health 2019:22(Suppl 3):S814
The patient perspective in health technology assessment reimbursement decisions for orphan drugs across different countries
Nicholson L, Langham S, Adkins E. The patient perspective in health technology assessment reimbursement decisions for orphan drugs across different countries. Value Health 2019:22(Suppl 3):S860
Transparency in decision modelling: what, why, who and how?
Sampson CJ, Arnold R, Bryan S, Clarke P, Ekins S, Hatswell A, Hawkins N, Langham S, Marshall D, Sadatsafavi M, Sullivan W, Wilson ECF, Wrightson T. Transparency in decision modelling: what, why, who and how? Pharmacoeconomics 2019;37(11):1355–69
Choosing the right software for HTA economic models: a comparison of four programmes recommended by the National Institute for Health and Care Excellence
Wright A, Embleton N, Langham S. Choosing the right software for HTA economic models: a comparison of four programmes recommended by the National Institute for Health and Care Excellence. Value Health 2018;21(Suppl 3):S380
Health technology assessment of companion diagnostics alongside therapeutic agents in oncology: experience of the NICE technology appraisal programme
Langham S, Lewis J. Health technology assessment of companion diagnostics alongside therapeutic agents in oncology: experience of the NICE technology appraisal programme. Value Health 2018;21(Suppl 3):S272